Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001806 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
A Phase 4 study of Cataracts, sponsored by Frank A. Bucci, Jr., M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT01001806: Completed Phase 4 study of Cataracts, sponsored by Frank A. Bucci, Jr., M.D..
NCT01001806 is a Phase 4 study of Cataracts that has completed, run by Frank A. Bucci, Jr., M.D.. The registered enrollment target is 126 participants, above the 82-participant average among 8 other Cataracts trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01001806, a Phase 4 study of Cataracts, has completed, sponsored by Frank A. Bucci, Jr., M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.
Conditions Studied
Interventions
- DRUG nepafenac 0.1%
- DRUG Ketorolac Tromethamine 0.45%
- DRUG bromfenac 0.09%
Study Locations (1)
Pennsylvania
- Bucci Laser Vision Institute - Wilkes-Barre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT01001806 record still lists
NCT01001806 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 8 other Cataracts trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 3 interventions - of which nepafenac 0.1% is the first listed.
NCT01001806 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01001806 about?
NCT01001806 is a clinical study titled "A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification". Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue d...
What is the current status of trial NCT01001806?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 126 participants. The study started on 2009-10. Estimated completion is 2010-01.
What conditions does trial NCT01001806 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT01001806?
The interventions under investigation include: nepafenac 0.1% (DRUG), Ketorolac Tromethamine 0.45% (DRUG), bromfenac 0.09% (DRUG).
Who is sponsoring clinical trial NCT01001806?
This trial is sponsored by Frank A. Bucci, Jr., M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01001806 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01001806's enrollment target sits among peer trials
126 2nd of 8 the highest of 8 other Cataracts trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataracts trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia